Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor It is with interest that we read the article “Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin” published in JAMA Psychiatry.1 Through their survey study, Cicero and Ellis1 concluded that abuse-deterrent formulations (ADFs) can have the intended purpose of curtailing abuse, but only with limited effectiveness, and efforts to reduce opioid supply alone with ADF technology will not mitigate the opioid abuse program in the United States.
Ruan X, Chiravuri S, Kaye AD. Abuse-Deterrent Formulations of Prescription Opioids. JAMA Psychiatry. 2015;72(8):849–850. doi:10.1001/jamapsychiatry.2015.0721
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: